Connor Clark & Lunn Investment Management Ltd. established a new position in Kura Oncology by purchasing 996,114 shares. This investment is valued at approximately $10.9 million. The firm now holds a 1.12% stake in the biotechnology company.
CEO Troy Wilson purchased 100,000 shares in an open-market transaction earlier this week. Wilson’s acquisition totaled $1.24 million.
Analysts at Citizens JMP recently reiterated a Market Outperform rating for the company. This rating contributes to a generally optimistic sentiment regarding the stock.